[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-354201-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-354201-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","cancer-type-specific-variation-in-patterns-of-driver-alterations-across-50000-tumors","Cancer type-specific variation in patterns of driver alterations across 50,000 tumors","","The paper defines cancer type-specific patterns of somatic driver alterations by analyzing 54,331 tumors from 48,179 patients across 448 histological cancer subtypes. It reports 164 newly identified hotspots and shows that one-third of drivers occur in non-canonical contexts with distinct behaviors, including increased subclonality and later emergence. Gene fusion and co-occurring driver patterns relate to earlier disease onset, while ancestry-specific HLA-restricted driver neoantigens and somatic HLA loss influence T cell therapy eligibility and intrinsic resistance.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/cancer-type-specific-variation-in-patterns-of-driver-alterations-across-50000-tumors/354201/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/cancer-type-specific-variation-in-patterns-of-driver-alterations-across-50000-tumors/354201.png","ImageObject",300,407,{"name":42,"@type":43},"Adam","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-25","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What dataset and cancer scope does the study analyze?","Question",{"text":63,"@type":64},"The study analyzes 54,331 tumors from 48,179 patients spanning 448 histological cancer subtypes.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How many new driver hotspots are identified, and what is their significance?",{"text":68,"@type":64},"The study identifies 164 newly identified hotspots and shows that many drivers arise in non-canonical contexts with distinct properties.",{"name":70,"@type":61,"acceptedAnswer":71},"How do driver patterns relate to age of disease onset and immunotherapy eligibility?",{"text":72,"@type":64},"Within cancer types, gene fusions and co-occurring driver patterns indicate earlier disease onset. The work also identifies ancestry-specific HLA-restricted driver neoantigens that affect eligibility for T cell receptor therapy, and it links somatic HLA loss to cancer-type-specific intrinsic resistance.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},354201,1790232023,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":97,"preview_urls":146},1374404737137,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Author Manuscr ipt Author Manuscr ipt Author Manuscr ipt Author Manuscript  \n\n| | HHS Public Access\u003Cbr>Author manuscript\u003Cbr>Cancer Cell. Author manuscript; available in PMC 2026 May 23. |\n| --- | --- |\n\nPublished in final edited form as:  \nCancer Cell. 2026 May 11; 44(5): 1045–1062.e6. doi:10.1016/j.ccell.2026.03.003 .  \nCancer type-specific variation in patterns of driver alterations across 50,000 tumors  \nA full list of authors and affiliations appears at the end of the article.  \nSUMMARY  \nThe oncogenic impact of somatic driver alterations is shaped by tissue context. Classifying alterations by cancer type and evaluating their context-specific properties requires large cohorts of genomically profiled and clinically annotated tumors. Here, we define cancer type-specific patterns of driver alterations, including 164 newly identified hotspots, in 54,331 tumors from  \n48,179 patients spanning 448 histological cancer subtypes. One-third of all drivers arose in non-canonical contexts and exhibited distinct features, including increased subclonality, later emergence, and divergent biological properties. Within cancer types, gene fusions and other distinct patterns of co-occurring drivers are indicative of earlier age of disease onset. We  \nalso identify ancestry-specific differences in human leukocyte antigen (HLA)-restricted driver neoantigens affecting T cell receptor therapy eligibility, and demonstrate cancer-type-specific patterns of intrinsic resistance via somatic HLA loss. Our findings highlight that functional roles of driver alterations depend on the cancer types and clinical contexts in which they arise.  \nIn brief  \nBandlamudi et al. analyze 54,331 tumors across 448 cancer subtypes to define cancer type-specific patterns of driver alterations. They identify 164 new cancer hotspots and show that driver clonality, zygosity, age of disease onset associations, and HLA-dependent immunogenicity vary by tissue context, refining biological interpretation and clinical actionability.  \nGraphical Abstract  \nThis is an open access article under the CC BY-NC-ND license ([http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)).  \n*[Correspondence: bandlamc@mskcc.org](Correspondence: bandlamc@mskcc.org) (C.B.), [bergerm1@mskcc.org](bergerm1@mskcc.org) (M.F.B.) .  \nAUTHOR CONTRIBUTIONS  \nConceptualization, C.B. and M.F.B.; methodology, C.B., I.B., M.Z., S.N., S.A.S., W.K.C., M.A.P., and M.F.B.; software: C.B., I.B., M.Z., S.N., S.A.S., K.A., J.W., C.F., G.Z., H.Z., H.Z., R.M., R.K., K.P., M.W., J.G., and N.S.; formal analysis, C.B., D.M., I.B.,  \nM.Z., S.N., S.A.S., S.W., K.A., W.K.C., B.N., H.W., J.W., T.N.T, S.R., and I.O.; investigation, C.B., I.B., M.Z., M.V.G., S.N., S.A.S., M.Y.J., K.A., W.K.C., B.N., H.W., J.W., C.B., T.N.T, M.M., M.A.P., S.E.T., A.L.R, R. S., J.J., R.A.K., J.K.D., J.C., A. S., E.R., J.G., D.M., S.R., G.J., A.B., A.M., A.R.B., A. S., R.N.P, J.C., R.B., M.E.A., S.C., H.Y., N.R., M.T.A.D., C.A.K., R.Y., A.R.B., A.Z., M.L., N. S., D.B. S, and M.F.B. ; resources: C.B., I.B., E.C.H, J.G., T.A., N. S., D.B. S, and M.F.B. ; data curation: C.B., D.M, I.B., M.Z., S.N., S.A. S., M.A.P, S.E.T., R.H., R.K., J.J., A. S., K.H. S, R.R.K., H.A.R., C.F.F., P.R., E.R., Y.R.M., L.G.T.M., J.A.F., I.K.M., P.C., N.N. S., A.J.S., G.J.R., C.M.R., A.D., J.J.L., H.A.A., G.I., A.M.V., E.M.O., Z.K.S., M.E.R., D.C., R.Y., A.R.B., A.Z., and N.S.; writing – original draft: C.B. and M.F.B.; writing – review and editing: all authors; supervision: C.B., M.L., N.S., D.B.S., and M.F.B.; funding  \nacquisition: C.B., D.B.S., and M.F.B.  \nAuthor Manuscr ipt Author Manuscr ipt Author Manuscr ipt Author Manuscript  \nBandlamudi et al. Page 2  \nINTRODUCTION  \nCancer is a genetic disease defined by the serial acquisition of cell fitness-promoting mutations, referred to as “drivers.”1 Characterization of driver alterations is fundamental to understanding cancer pathogenesis, molecular classification of tumors","cbCaivyGq3jMCfJo","https://ap.wps.com/l/cbCaivyGq3jMCfJo","pdf",4342104,44,"English","# Summary\n# In brief\n# Graphical Abstract\n# Author Contributions\n# Introduction","[{\"question\":\"What dataset and cancer scope does the study analyze?\",\"answer\":\"The study analyzes 54,331 tumors from 48,179 patients spanning 448 histological cancer subtypes.\"},{\"question\":\"How many new driver hotspots are identified, and what is their significance?\",\"answer\":\"The study identifies 164 newly identified hotspots and shows that many drivers arise in non-canonical contexts with distinct properties.\"},{\"question\":\"How do driver patterns relate to age of disease onset and immunotherapy eligibility?\",\"answer\":\"Within cancer types, gene fusions and co-occurring driver patterns indicate earlier disease onset. The work also identifies ancestry-specific HLA-restricted driver neoantigens that affect eligibility for T cell receptor therapy, and it links somatic HLA loss to cancer-type-specific intrinsic resistance.\"}]","Cancer type-specific variation in patterns of driver alterations across 50,000 tumors | PDF",1790109444,111,[147,151,155,159,163],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/249cd3860e3759f2ab45c8d4ee9a21ee.webp",983,1272,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/90e75fac42af671573b8cb81677e81c4.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8d512191fc896a0de6577f2b2e1ce19d.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7c48b9102a4a9c0b3f607ace82c1fa9e.webp",980,1268,{"page_no":97,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/92305a0e227458ee3bed6245ee116eb0.webp",979,1267]